Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07790861
Starting soon Phase 3

A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

NCT07790861 · tracked via the Priya Life Science China tracker
Sponsor
Eli Lilly and Company
Phase
Phase 3
Started
2026-12
Last updated
2026-10-13

Condition(s) studied

ObesityOverweight

Investigational drug(s) / intervention(s)

Orforglipron →Placebo

Orforglipron: Administered orally.

Placebo: Administered orally.

Study summary

The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Have body mass index (BMI) ≥28.0 kilograms per square meter (kg/m2) and \<30 kg/m2 or ≥24.0 kg/m2 and \<28 kg/m2, and at least 1 of the following weight-related comorbidities at screening: * hypertension * dyslipidemia * obstructive sleep apnea * Fatty liver * cardiovascular disease * Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight Exclusion Criteria: * Have type 1 diabetes (T1D), type 2 diabetes (T2D), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma * Have a self-reported change in body weight \>5 kg within 90 days prior to screening * Had chronic or acute pancreatitis any time prior to screening * Have family (first-degree relative) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome

Primary outcome measure(s)

  • Mean Percent Change From Baseline in Body Weight — Baseline, Week 48

Trial sites (13)

FacilityCityRegionStatus
Sichuan Provincial People's Hospital Chengdu China
Zhujiang Hospital Guangzhou China
The first Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China
Zhejiang Provincial People's Hospital Hangzhou China
The Fourth Affiliated Hospital of Harbin Medical University Harbin China
The Second People's Hospital of Hefei Hefei China
Jinan Central Hospital Jinan China
The First Affiliated Hospital of Henan University of Science &Technology Luoyang Shi China
Jiangxi Provincial People's Hospital Nanchang China
Nanjing First Hospital Nanjing China
The Second Affiliated Hospital of Nanjing Medical University Nanjing China
Jiangsu Province Hospital Nanjing China
Shanghai Sixth People's Hospital Shanghai China

More Eli Lilly and Company trials in China

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease Recruiting
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) Active, not recruiting
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors Active, not recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes Recruiting

Other trials for the same condition

Phase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity Starting soon
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes Recruiting
Clinical Classification and Imaging Markers in Patients of Obesity Enrolling by invitation
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity Active, not recruiting
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07790861 on ClinicalTrials.gov ↗ ← All trials in China